164 related articles for article (PubMed ID: 35855557)
1. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.
Freedman BL; Berg DD; Scirica BM; Bohula EA; Goodrich EL; Sabatine MS; Morrow DA; Bonaca MP
Clin Cardiol; 2022 Aug; 45(8):831-838. PubMed ID: 35855557
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50.
Berg DD; Freedman BL; Bonaca MP; Jarolim P; Scirica BM; Goodrich EL; Sabatine MS; Morrow DA
J Am Heart Assoc; 2021 May; 10(9):e018673. PubMed ID: 33884889
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
[TBL] [Abstract][Full Text] [Related]
4. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
5. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
8. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
9. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Metab; 2021 Sep; 47(5):101249. PubMed ID: 33744399
[TBL] [Abstract][Full Text] [Related]
10. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
Berg DD; Wiviott SD; Scirica BM; Zelniker TA; Goodrich EL; Jarolim P; Mosenzon O; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Langkilde AM; Raz I; Braunwald E; Sabatine MS; Morrow DA
Diabetes Care; 2021 Nov; 44(11):2573-2581. PubMed ID: 34535469
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
[TBL] [Abstract][Full Text] [Related]
12. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
13. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
14. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
15. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
[TBL] [Abstract][Full Text] [Related]
16. Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score.
Lin Y; Shao H; Shi L; Anderson AH; Fonseca V
Diabetes Obes Metab; 2022 Nov; 24(11):2203-2211. PubMed ID: 35801340
[TBL] [Abstract][Full Text] [Related]
17. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
18. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
[TBL] [Abstract][Full Text] [Related]
19. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
